Triple negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis and high mortality rate. The tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) plays an important role in cell proliferation and cell migration by negatively regulating the PI3K/Akt pathway. PTEN is downregulated by microRNAs in multiple cancers. However, few microRNAs have been reported to directly target PTEN in TNBC. In this study, microRNAs predicted to target PTEN were screened by immunoblotting and luciferase reporter assays. Expression levels of microRNA-498 (miR-498) were measured by TaqMan microRNA assays. We performed clonogenic, cell cycle and scratch wound assays to examine the oncogenic role of miR-498. We demonstrated that miR-498 directly targeted the 3′untranslated region of PTEN mRNA and reduced PTEN protein levels in TNBC cells. Compared with the non-tumorigenic breast epithelial cell line MCF-10A, TNBC cell lines overexpressed miR-498. Moreover, miR-498 promoted cell proliferation and cell cycle progression in TNBC cells in a PTEN-dependent manner. Suppressing miR-498 overexpression impaired the oncogenic effects of miR-498 on cell proliferation and cell migration. This study identified a novel microRNA (miR-498) overexpressed in TNBC cells and its oncogenic role in suppressing PTEN. These results provide new insight into the downregulation of PTEN and indicate a potential therapeutic target for treating TNBC.
Introduction
Breast cancer (BCa) is the most frequently diagnosed cancer in women worldwide (1) . As a highly heterogeneous disease, BCa can be classified into intrinsic subtypes depending on the expression of molecular markers, such as the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2)/Neu (2) . Triple negative breast cancer (TNBC) is a subtype of BCa in which ER, PR and HER-2 are not expressed (2, 3) . Although TNBC cases account for only 10-15% of all BCa cases, the prognosis of TNBC patients is poor when compared with that of other BCa subtypes in which ER and PR expression is detected and for which hormone-replacement therapy can often be applied with good outcomes (4) . Therefore, despite progress made for these other BCa subtypes, it is critical to identify novel potential therapeutic targets for treating TNBC.
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a dual phosphatase and acts as a tumor suppressor via its dephosphorylation of phosphatidylinositol 3, 4,5-trisphosphate (PIP3) (5) (6) (7) (8) . PIP3 is an important second messenger that activates the kinase Akt (formerly protein kinase B) by phosphorylation (7) . Activated Akt is a survival factor and is involved in cell proliferation and cell migration through the PI3K/Akt pathway (9) (10) (11) (12) . PTEN plays a crucial role in suppressing the development of cancer and is one of the most commonly inactivated tumor suppressors in BCa (5, 6, 13) . PTEN inactivity is associated with large tumor sizes, considerable lymph node metastasis and an aggressive triple negative phenotype (13) . PTEN expression is much lower in BCa tissue (57.5%, 84/117) than in normal breast tissue (100%, 10/10); however, PTEN mutation rates are approximately 5% in BCa, which indicates that other mechanisms negatively regulate PTEN expression in these tumors (14, 15) . Recent studies have revealed that microRNAs (miRNAs) can regulate PTEN expression and function (16) (17) (18) .
miRNAs are a type of small non-coding RNA and are 19-25 nt in length (19) . Although they do not encode proteins directly, miRNAs usually bind to the 3′untranslated region (3′UTR) of a protein-encoding mRNA and regulate protein expression by inhibiting target mRNA translation or promoting mRNA degradation (20, 21) . In prior studies, some miRNAs inactivated PTEN and acted as oncogenic players in multiple cancers (17, 18, 22, 23) . For instance, miR-221 and miR-222 were over-expressed in nonsmall cell lung cancer and hepatocellular carcinoma and promoted tumorigenesis by targeting PTEN (17) . However, studies of PTEN regulation by miRNAs in TNBC are limited and provide unclear results.
In this study, to identify novel miRNAs targeting PTEN, we screened 19 miRNAs and discovered that microRNA-498 (miR-498) directly bound to the 3′UTR of PTEN mRNA to negatively regulate PTEN expression. Moreover, miR-498 played an oncogenic role in cell proliferation and migration in TNBC cell lines through suppressing PTEN. These results indicate that miR-498 could be used as a potential target for treating TNBC.
Materials and methods

Cell culture, DNA transfection and DNA transduction
Human HEK293, HEK293T and MCF-7 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). MDA-MB-231, MDA-MB-157, MCF-10A, BT-549, Hs578T and MDA-MB-453 were provided by Drs. David Brindley and Manijeh Pasdar (University of Alberta, Edmonton, AB, Canada). These cell lines were cultured and frozen in liquid nitrogen immediately upon arrival; the cells were routinely tested by PCR for mycoplasma contamination by the following primers: Myco_fw1: 5′-ACACCATGGGAGCTGGTAAT-3′, Myco_rev1: 5′-CTTCATCGACTTTCAGACCCAAGGCA-3′. MDA-MB-231, BT-549, Hs578T, MDA-MB-157 (TNBC model), HEK293, HEK293T and MCF-7 (ER+ and PR+) cells were transfected using the calcium phosphate method or retroviral transduction as previously described (24) .
DNA constructs
The PTEN 3′UTR was cloned from HEK293 genomic DNA by PCR and inserted into the pMIR-REPORT TM luciferase expression vector (Ambion). The PTEN open reading frame (ORF) or PTEN ORF plus 3′UTR was cloned into the pBabe-MN-Ires-green fluorescent protein (GFP) expression vector. The sequences of all miRNAs were obtained from the ORIGENE online database (http://www.origene.com) and inserted in the pcDNA3.1 expression vector (Invitrogen). The empty expression vector or scramble-miR was considered as controls (Cont.-miR). For the miR-498 decoy construct, double strands of oligonucleotides containing six repeated sequences that were completely complementary to miR-498 were synthesized (Life Technologies) and inserted into the pMIR-REPORT TM luciferase reporter. The PTEN mutation was synthesized by Life Technologies. The PTENshRNA [AGTAGAGGAGCCGTCAAAT, (25) ] was cloned into pSUPER-retropuro vector (Oligoengine) according to the manufacturer's instructions. All of these constructs were confirmed by DNA sequencing (U. Alberta).
Retroviral transduction
miR-498 was inserted in the pBabe-MN-Ires-GFP vector. The pBabe-MNIres-GFP-miR-498 and pCL-Ampho retrovirus packaging vectors were cotransfected into HEK293T cells at a ratio of 1:1, and the viral supernatants were harvested 48 h after transfection. Viral titers were 1 × 10 6 to 1 × 10 7 PFU/ml according to plaque assays using HEK293 cells (26) . Viral supernatants with equal plaque forming units (PFUs) were added to cell dishes with 8 µg/ml polybrene to enhance viral transduction.
RNA extraction and quantitative reverse transcription PCR
Total RNA was extracted with Trizol (Invitrogen). To quantify mature miR-498, quantitative reverse transcription (qRT)-PCR was performed using the TaqMan microRNA assay (Applied Biosystems, miR-498 assay ID: 001044, U6 snRNA assay ID: 001973). The expression of miR-498 was normalized to the expression of U6 snRNA by the comparative Ct method as previously described (27) .
Immunoblotting analysis and antibodies
Cells were lysed in radio-immune precipitation assay (RIPA) lysis buffer supplemented with a protease inhibitor mix (Roche). A total of 50 µg protein was loaded and run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (USA) gels and then transferred to polyvinylidene difluoride membranes for immunoblotting with antibodies. The antibodies used were anti-PTEN (Santa Cruz, SC-7974), anti-β-actin (Sigma, A3854), anti-p-Akt (Santa Cruz, SC-7985-R), anti-Akt (Santa Cruz, SC-5298), anti-GFP (Santa Cruz, SC-9996) and anti-Flag M5 (Sigma, F4042).
Clonogenic assay
Exponentially growing cells were trypsinized and counted. Appropriate numbers of cells were seeded onto 60 mm dishes and incubated for 10-14 days. Colonies with over 50 cells were counted to determine the colony number ratio. The colony number ratio was the average of three independent experiments.
MTT assay
BCa cells were transduced with miR-498 and PTEN ORF or siPTEN, respectively, and 5000 cells/well were then seeded onto 96 well plates. After 48 h, 50 µl MTT (5 mg/ml) was added to the media in each well and incubated in 37°C for 4 h. The media was removed and 150 µl MTT solution was added to each well, and after 30 min the optical density (OD) 550 value was measured.
Luciferase reporter assay
HEK293 cells were transfected with the constructed luciferase reporters, β-galactosidase plasmids and miRNA. After 48 h, the cells were lysed with reporter lysis buffer (Promega). The luciferase activity was measured and normalized to the β-galactosidase activity as previously described (28) .
Cell cycle assay
MDA-MB-231 and BT-549 cells were transduced with miR-498. After 48 h, the cells were washed twice, fixed in 70% ethanol, treated with 50 µg/ml RNase A and labeled with 50 µg/ml propidium iodide for 3 h at 4°C. Then the cells were analyzed by flow cytometry (Becton Dickinson). The data were analyzed using FlowJo software (TreeStar).
Scratch wound assay
MDA-MB-231 and BT-549 cells were transduced with miR-498 or the miR-498 decoy. After 48 h, the cells were subjected to scratch wounding in a 24-well plate (28) . Two wound tracks were introduced by scraping the cell monolayer with a pipette tip (20 µl), and the two tracks crossed at the 
Statistical analysis
Data are presented as the means ± standard deviation (SD). Statistical comparisons were performed using unpaired two-tailed Student's t-tests.
Results
Identification of miRNA s regulate PTEN in BCa cell lines
To identify miRNAs that could suppress PTEN protein levels, five miRNA databases (Miranda, RNA22, miTarget, PicTar and TargetScan) were accessed to predict miRNAs that could potentially bind to PTEN mRNA. Nineteen of the predicted miRNAs were selected for further screening ( Figure 1A ). Figure 1D ). The mRNA levels of PTEN in Hs578T and MDA-MB-231 were significantly lower than in MCF-10A ( Figure 1E ). Moreover, miR-498 expression was negatively correlated with the overall survival of patients with BCa. Kaplan-Meier survival curves revealed that patients with BCa with a high level of miR-498 had a significantly lower overall survival time [ Figure 1F and G, kmplot.com, (31)]. Our findings suggested that there was probably an inverse correlation between miR-498 and PTEN expression levels in BCa cell lines.
miR-498 negatively regulates PTEN protein levels in TNBC cell lines
Because TNBC is the subtype of BCa with the highest rate of mortality, we investigated whether miR-498 overexpression reduced PTEN protein levels in MDA-MB-231 and MDA-MB-157 cells. and that miR-498 levels are negatively correlated with PTEN protein levels in TNBC cell lines.
To determine the functional roles of endogenous miR-498, a miR-498 decoy was constructed in which six tandem miR-498 sequences complementary to miR-498 were linked to a luciferase reporter gene [ Figure 2C , (28)]. The luciferase activity of the miR-498 decoy was significantly reduced by miR-498 when miR-498 and the miR-498 decoy were co-transfected into HEK293 cells; however, the luciferase activity of the miR-498 decoy was not affected by either the control miRNA or miR-1-1 ( Figure 2D ). Our findings indicated that the miR-498 decoy was highly specific for miR-498 and was capable of binding to miR-498.
To test whether the miR-498 decoy could suppress endogenous miR-498 and restore PTEN expression, a stable miR-498 overexpressing Hs578T cell line was generated. The plasmid expressing miR-498 was transfected into Hs578T cells, and hygromycin (200 ng/ml) was used to select cells stably overexpressing miR-498; cells were also transfected with control miRNA and treated with the same concentration of hygromycin. After 2 weeks of selection, stable miR-498-overexpressing cells were obtained. PTEN protein levels were then measured by immunoblotting, and miR-498 overexpression was confirmed by qRT-PCR. Endogenous PTEN levels were significantly lower in the miR-498-overexpressing cells than in the stable control miRNA cells ( Figure 2E , left and middle panels). miR-498 expression was confirmed by qRT-PCR ( Figure 2E , right panel). Next, the miR-498 decoy was transduced into the stable miR-498-overexpressing Hs578T cells to investigate its role in suppressing miR-498 and restoring PTEN. As shown in Figure 2F (left and middle panels), compared with the control miRNA decoy, the miR-498 decoy significantly restored PTEN protein levels. miR-498 expression was also suppressed by the miR-498 decoy and reached only 0.25% of the miR-498 expression level in the control miRNA decoytransduced cells ( Figure 2F , right panel). These results indicated that the miR-498 decoy suppressed miR-498 and restored PTEN protein levels and that the miR-498 decoy could be used as an inhibitor of miR-498 overexpression.
PTEN is a direct target of miR-498
To identify the miR-498 binding site in the 3′UTR of PTEN mRNA, we used the microRNA.org database to search for the putative binding sites. Then, we cloned the putative binding sites into a luciferase reporter construct to examine their binding with miR-498 in vitro. The luciferase reporter and miR-498 were cotransfected into HEK293 cells, which have a high transfection efficiency and are widely used in validation of miRNA targets (32) . After 48 h, the cells were lysed, and luciferase activity was measured. The results of the luciferase reporter assays revealed that the putative binding site at 833 to 855 bp on the 3′UTR of PTEN mRNA was the most dominant binding site ( Figure 3A) . Four miRNAs as indicated were co-transfected with the PTEN mRNA 3′UTR luciferase reporter into HEK293 cells to confirm their binding to the 3′UTR of PTEN mRNA. Of the four miRNAs, compared with the control miRNA, miR-498 significantly decreased luciferase reporter activity, which was consistent with miR-498 binding to the 3′UTR of PTEN mRNA ( Figure 3B) .
Furthermore, the overexpression of miR-498 reduced luciferase activity by more than 30% compared with the control miRNA ( Figure 3C and D) . These results suggest that miR-498 can bind to this site to inhibit PTEN expression. Moreover, mutations to this binding site abolished the reduced luciferase activity induced by miR-498 overexpression ( Figure 3E and F) , which confirmed that miR-498 was capable of binding to this site on the 3′UTR of PTEN mRNA. To evaluate the effect of miR-498 on PTEN protein levels in HEK293 cells, we generated a Flag-tagged PTEN construct that contained the ORF and 3′UTR of PTEN mRNA to mimic PTEN mRNA. We then co-transfected this PTEN construct with miR-498 into HEK293 cells. Flag-PTEN levels were examined by immunoblotting, and exogenous Flag-PTEN was significantly decreased by approximately 50% by the overexpression of miR-498 compared with control miRNA (Figure 3G and H) . miR-498 expression levels were also measured by qRT-PCR ( Figure 3I) . Notably, the levels of PTEN protein did not change when cells were transfected with plasmids expressing the PTEN-coding sequence (without the 3′UTR of PTEN) along with miR-498 (data not shown). Similar results were obtained from H1299 and MCF-7 cells (data not shown). These results are consistent with miR-498 directly bound to the 3′UTR of PTEN mRNA to negatively regulate PTEN protein levels.
miR-498 plays an oncogenic role dependent on PTEN suppression in TNBC cells
It has been reported that PTEN acts as a tumor suppressor and suppresses cell proliferation and cell cycle progression by negatively regulating the p-Akt signaling pathway (7, 8, 33, 34) . On the basis of the results described earlier, miR-498 overexpression suppressed PTEN in the TNBC cell lines MDA-MB-231 and MDA-MB-157 (Figure 2A Figure 4A) ; the expression of miR-498 was determined by qRT-PCR ( Figure 4B ). However, no obvious changes in p-Akt protein levels were observed in PTEN null BT-549 cells overexpressing miR-498 ( Figure 4C and D) . To determine the oncogenic effects of miR-498 overexpression, cell clonogenic assays were performed. As shown in Figure 4E , miR-498 significantly increased the colony formation ratio in MDA-MB-231 cells. However, no significant changes in the colony formation ratio were found in BT-549 (PTEN-null) cells ( Figure 4F ). These results support that miR-498 promoted cell proliferation through suppressing PTEN and activating p-Akt signaling. PTEN has been reported to induce cell cycle arrest through negative regulation of the PI3K/Akt pathway (33, 34) . To determine the effects of miR-498 on promoting cell cycle progression in TNBC cells by suppressing PTEN, MDA-MB-231 and BT-549 cells were transduced with miR-498. The overexpression of miR-498 promoted cell cycle progression in MDA-MB-231 cells, and their G1/S ratio was 1.18; the G1/S ratio of cells transduced with the control miRNA was 2.06 ( Figure 4G ). However, no differences in the G1/S ratio were shown in PTEN null BT-549 cells transduced with miR-498 or control miRNA ( Figure 4H ), which suggested that miR-498-overexpression-induced cell cycle arrest was dependent on PTEN repression. Together, these results demonstrated that miR-498 promoted cell proliferation and cell cycle progression in a PTEN-dependent manner.
Introduction of the PTEN ORF rescues the phenotypes associated with miR-498 overexpression
As described earlier, overexpression of miR-498 exhibited an oncogenic effect. To determine whether the oncogenic effect of miR-498 overexpression was dependent on PTEN suppression, we introduced PTEN ORF to rescue the suppression of PTEN by miR-498 overexpression. As shown in Figure 5A , the decreased protein levels of PTEN by miR-498 overexpression were largely rescued by introducing PTEN ORF and the enhanced p-Akt levels were also inhibited by PTEN ORF in MDA-MB-231 cells. Furthermore, we compared the effect of miR-498 overexpression and siRNA (siPTEN) depletion of PTEN on cell proliferation and cell migration. Similar to the PTEN depletion, overexpression of miR-498 decreased the levels of PTEN protein and increased p-Akt levels ( Figure 5B ). As expected, cell viability was significantly enhanced by miR-498 overexpression and inhibited by the introduced PTEN ( Figure 5C ). Moreover, cell migration was significantly promoted by overexpression of miR-498 and inhibited by restored PTEN (Figure 5E ). In terms of cell proliferation and cell migration, miR-498 overexpression was comparable to siPTEN in MDA-MB-231 cells ( Figure 5D and F) . Taken together, our results indicate that the introduced PTEN ORF rescues the phenotype of miR-498 overexpressing cells.
In addition, we compared miR-498 with miR-425, which is an oncogenic PTEN-targeted miRNA, as a positive control. We observed that both miR-498 and miR-425 decreased endogenous PTEN levels and increased p-Akt levels in MDA-MB-231 and MCF-7 (Supplementary Figure 1A 
The PTEN-dependent oncogenic effect of miR-498 overexpression is inhibited by the miR-498 decoy
It has been established that PTEN suppresses cell migration (35, 36) . To determine whether miR-498 overexpression affects cell migration through suppressing PTEN, we used wound-healing assays to visualize the migration of TNBC MDA-MB-231 and BT-549 cells transduced with miR-498 or the miR-498 decoy. As shown in Figure 6A , 24 h after wounding, miR-498 overexpression significantly enhanced the migration of MDA-MB-231 cells (PTEN wt) compared with that of cells transduced with control miRNA or the control miRNA decoy. However, the miR-498 decoy blocked the enhanced cell migration induced by miR-498 overexpression. These results revealed that miR-498 overexpression promoted cell migration and that the miR-498 decoy could be used as an anti-miR-498 agent to inhibit the function of miR-498. The relative blank areas of the wounds were measured to evaluate cell migration. Statistical analyses of the cell migration are shown in the lower panel of Figure 6A . Furthermore, in BT-549 cells (PTEN null) at 24 h, miR-498 overexpression did not enhance cell migration, which suggested that the enhanced cell migration was dependent on PTEN. In addition, no significant differences in cell migration were found between miR-498-overexpressing cells and miR-498 decoy-expressing cells ( Figure 6B ).
To confirm that the oncogenic effect of miR-498 overexpression on cell proliferation was inhibited by the miR-498 decoy, miR-498 and the miR-498 decoy were transduced into the TNBC cell lines MDA-MB-231 and BT-549. As shown in Figure 6C , miR-498 increased the colony numbers in MDA-MB-231 cells, whereas the miR-498 decoy significantly reduced the colony numbers. These results support that miR-498 overexpression promoted proliferation in MDA-MB-231 cells, and this oncogenic effect was inhibited by the miR-498 decoy. In contrast, in BT-549 cells (PTEN null), no significant changes in the colony numbers were found after transducing miR-498 or the miR-498 decoy ( Figure 6D ). These results indicated that the oncogenic role of miR-498 was PTEN-dependent in vitro. In addition, the protein levels of PTEN and p-Akt in MDA-MB-231 and BT-549 cells transduced with miR-498 or the miR-498 decoy were measured. Consistently, p-Akt was activated by miR-498 overexpression and suppressed by the miR-498 decoy in PTEN wild-type MDA-MB-231 cells ( Figure 6E ). However, in PTEN null BT-549 cells, p-Akt levels were not changed by miR-498 overexpression ( Figure 6F ). On the basis of these data, we concluded that the oncogenic role of miR-498 was PTEN-dependent and can be inhibited by the miR-498 decoy.
Discussion
The tumor suppressor PTEN is a negative regulator of the PI3K/ Akt pathway and is involved in cell proliferation, cell migration and cell cycle arrest (7, 8, 27, (33) (34) (35) (36) (37) . PTEN has been reported to be absent or expressed at low levels in multiple cancers, e.g. prostate cancer, gastric cancer, colorectal cancer, non-small cell lung cancer and BCa (38) (39) (40) (41) . Recent studies have shown that reduced PTEN expression is more common in BCa tissues than normal breast tissues and is positively associated with tumor size, lymph node metastasis and an aggressive triple-negative phenotype. Taken together, these findings support a role that the tumor suppressor PTEN plays in the development of TNBC (13) . Due to its poor prognosis and the lack of effective therapies, TNBC is the most lethal subtype of BCa (3). The median survival of metastatic TNBC patients is only 13 months (42) . Therefore, it is urgent and necessary to find effective targets to prevent the progression of TNBC. In this study, we aimed to investigate the relation of TNBC and oncogenic miRNAs that can suppress PTEN.
miRNAs are one of the mechanisms through which PTEN can be inactivated. In fact, PTEN is suppressed by miRNAs in multiple cancers. Meng et al. (43) revealed that miR-21 downregulated PTEN in hepatocellular cancer, and Nip et al. (44) identified that overexpressing the oncogenic miR-4534 negatively regulated PTEN in prostate cancer. However, in TNBC, studies of PTEN regulation by miRNAs are limited. In this study, we screened predicted PTEN-targeting miRNAs and identified that miR-498 is overexpressed in TNBC cell lines and suppresses PTEN by directly binding to the 3′UTR of PTEN mRNA.
The role of miR-498 in cancers appears to be unclear. miR-498 is expressed at low levels in non-small cell lung cancer and ovarian cancer (45, 46) . However, Matamala et al. (47) reported miR-498 overexpression in TNBC tissues according to microarray analyses, and we detected miR-498 overexpression in TNBC cell lines according to the qRT-PCR analyses in our study. In addition, miR-498 is significantly higher in metastatic medullary thyroid carcinoma than in primary medullary thyroid carcinoma (48) . These results indicate the diversity of miR-498 expression profiles in different tissues. Furthermore, in addition to PTEN, other targets of miR-498 have been reported. For instance, telomerase reverse transcriptase enhances cell growth in an ER-α-dependent manner. Vitamin D-induced miR-498 overexpression targets telomerase reverse transcriptase mRNA and suppresses telomerase reverse transcriptase levels in ovarian cancer cells, and miR-498 functions as a tumor suppressor (49) . However, in TNBC, which has no ER-α expression, miR-498 is highly expressed in tissues and cell lines and negatively regulates the tumor suppressor PTEN, which contributes to oncogenesis. Therefore, the diversity of miR-498 targets and expression levels might explain the conflicting reports of the effects of miR-498.
In conclusion, our data revealed that miR-498 is overexpressed in TNBC cells and acts as an oncogenic factor by negatively regulating the tumor suppressor PTEN. Our findings demonstrated that the oncogenic effect of miR-498 is dependent on PTEN suppression. This study expands our understanding of the function of miR-498 and provides new information for the development of TNBC therapies.
